Cyclic polypeptides for PCSK9 inhibition
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
1. A bicyclic polypeptide compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The bicyclic polypeptide compound of claim 1 , having the following structure:
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the bicyclic polypeptide compound of claim 1 and a pharmaceutically acceptable carrier.
4. A method of reducing low density lipoprotein (LDL) cholesterol level in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the bicyclic polypeptide compound of claim 1 .
5. The method of claim 4 , wherein the subject has hypercholesterolemia.
6. The method of claim 4 , wherein the administration is selected from the group consisting of oral, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, and intravitreal.
7. A method of treating hypercholesterolemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the cyclic bicyclic polypeptide compound of claim 1 .
8. The method of claim 7 , wherein the subject further suffers from a disease that shows comorbidity with hypercholesterolemia.
9. The method of claim 7 , wherein the administration is selected from the group consisting of oral, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, and intravitreal.
10. The method of claim 8 , wherein the disease that shows comorbidity with hypercholesterolemia is selected from the group consisting of nephrotic syndrome, kidney failure, coronary artery disease, atherosclerosis, stroke, peripheral vascular disease, diabetes, and high blood pressure.
11. A method of inhibiting PCSK9 activity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the bicyclic polypeptide compound of claim 1 .
12. A method of inhibiting PCSK9 activity in a cell comprising contacting the cell with the bicyclic polypeptide compound of claim 1 .
13. A method of inhibiting the interaction between PCSK9 and the EGF-A domain of LDLR in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the bicyclic polypeptide compound of claim 1 .